Kornimate/medical-research-clean huggingface dataset:
influence of training intensity in coronary artery disease

Conditions: Coronary Artery Disease

Summary: coronary artery disease (cad) is associated with high mortality worldwide. narrowing of the coronary arteries can cause an acute myocardial infarction. patient with cardiac ischemia are often treated with percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg). following hospitalisation, the patients are offered to attend a classical rehabilitation program with moderate exercise intensity. current exercise program for cardiac rehabilitation has proven to reduce cardiovascular risk factors 1. is it possible to improve the exercise capacity and risk profile even more if the exercise program includes more vigorous training? the program starts one week after the cardiac incident (ami, pci or cabg) and takes 12 weeks to complete. patients with heart failure and valvular disease are excluded. first ventilatory threshold (vt1) and second ventilatory threshold (vt2) are determined during cycloerometry. vt2 reflects aerobic-anaerobic transition and therefore the aerobic functional capacity2. exercise load reached at vt2 is used to determine the training load during rehabilitation. the research goal is to investigate the influence of training intensity on the exercise capacity and risk profile of cad patients.


Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction (ami), who underwent a percutaneous coronary intervention (pci) or coronary artery bypass grafting (cabg). the 12-week program must be completed. exclusion criteria: * patients with heart failure (hfpef and hfref with ejection fraction ≤40%) and valvular heart disease.
post-transplant cancer incidence and survival in patients with or without pre-transplant cancer

Conditions: Neoplasms; Kidney Failure

Summary: patients with previous malignancies have increasingly been accepted for renal transplantation. however, post-transplant malignancy risk and survival rates of these patients are unknown. our aim was to assess if previous malignancies pose an unnecessarily high risk of post-transplant malignant tumours and if the organs as a resource are too limited for investment in this patient group.


Eligibility criteria:
inclusion criteria: * kidney transplanted patients from january 1982 through december 2013 with or without a pre transplant cancer. exclusion criteria: * simultaneous kidney+pancreas transplantation. * islet cell transplanted patients * undiagnosed malignancies at the time of transplantation * death within a week after transplantation * first transplantation at another hospital
upper airways cephalometric measures compared to skeletal class and divergence

Conditions: Skeletal Malocclusion

Summary: the aim of the present study is to investigate the baseline upper airways dimensions in adult patients belonging to all skeletal classes

lateral cephalometric radiographs of adult orthodontic patients referring for orthodontic consultation at the unit of orthodontics and pediatric dentistry, section of dentistry, department of clinical, surgical, diagnostic and pediatric sciences, university of pavia, 27100 pavia, italy, will be collected for the study according to the inclusion criteria. for each lateral cephalometric radiograph, a cephalometric tracing will be performed with deltadent software (version 2.2.1, outside format, spino d'adda, italy). riedel's anb angle \[riedel 1952\] has been adopted to determine patients' skeletal class. steiner's sn\^gogn angle \[steiner 1953\] will be used to evaluate skeletal divergence. biprotrusion will be assessed for sna \> 84° and snb \> 82°, while biretrusion for sna \< 80° and snb \< 78°. sample size calculation was performed with "soft palate length" as primary outcome. considering alpha = 0.05 and power = 95%, an expected mean value of 31.05 with a standard deviation of 4.16 was hypothesized, with an expected mean difference of 3.34 \[sprenger et al. 2017\], therefore 40 patients per group were required. statistical analysis will be conducted with r® software (version 3.1.3 r development core team, r foundation for statistical computing, wein, austria). for each cephalometric measure belonging to the three skeletal classes, descriptive statistics (mean and standard deviation) will be calculated. appropriate statistical tests will be used to assess data normality and multiple comparisons. linear regressions will be performed between upper airways diameters and sna, snb, anb, sn\^gogn, anspns\^gogn, pt, pl, sex and age.

Eligibility criteria:
inclusion criteria: * patients with permanent dentition * caucasian patients * patients with one lateral cephalometric digital radiograph executed in natural head position (patients were asked to keep the teeth in contact and the lips relaxed). exclusion criteria: * maxillo-facial traumas * nasopharyngeal pathologies * craniofacial dysmorphisms * orthognatic surgery * radiographs not performed in natural head position * unsuitable radiographs

Keywords: upper airways dimensions skeletal class skeletal divergency
xingnaojing for moderate-to-severe acute ischemic stroke (xmas)

Conditions: Acute Ischemic Stroke

Summary: the main purpose of this trial is to determine whether xingnaojing, intravenously administered within 24 hours of symptom onset, improves the 3-month outcome in participants with acute ischemic stroke.

xingnaojing is widely used in china, but there is lack of high-quality evidence of its efficacy for acute ischemic stroke currently. the primary hypothesis of this trial is that xingnaojing will increase the proportion of people alive and independent at three months. xingnaojing, combined with guidelines-based standard care, will be compared to standard care alone in patients with acute ischemic stroke within 24 hours of symptom onset. all patients will have a national institutes of health stroke scale (nihss) entry score of 5-20. patients in each group will be treated according to the guidelines-based standard care, including intravenous thrombolysis if appropriate. the primary outcome will be determined at 3 months.

Eligibility criteria:
inclusion criteria: * acute ischemic stroke within 24 hours of symptom onset. * national institutes of health stroke scale score ≥ 5 and ≤ 20. * age ≥ 35 and ≤ 80 years. * patient or legally authorized representative has signed informed consent. exclusion criteria: * planned or already received endovascular treatment. * suspected secondary stroke caused by tumor, brain trauma, or hematologic diseases. * already dependent in activities of daily living before the present acute stroke (defined as modified rankin scare score ≥2 ). * other conditions that lead to motor dysfunction (e.g. severe osteoarthrosis, rheumatoid arthritis). * significant renal or hepatic insufficiency (defined as a serum creatinine concentration, alanine aminotransferase, or aspartate aminotransferase value that is twice greater than the upper limit of normal). * life expectancy of 90 days or less due to other life threatening illness (e.g. advanced cancer). * other conditions that render outcomes or follow-up unlikely to be assessed.. * known to be pregnant or breastfeeding. * currently receiving an investigational drug.

Keywords: acute ischemic stroke xingnaojing injection randomized controlled trial traditional chinese medicine
efficacy study of nebulized td-4208 for chronic obstructive pulmonary disease (copd)

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Summary: the purpose of this study is to measure the effectiveness and safety of td 4208, an investigational drug being developed to treat people with moderate to very severe copd, compared to placebo, a treatment without activity.


Eligibility criteria:
inclusion criteria: * subject is a male or female subject 40 years of age or older exclusion criteria: * females who are pregnant, lactating, breast-feeding or planning to become pregnant during the study

Keywords: chronic obstructive pulmonary disease, copd
natural history studies of mucopolysaccharidosis iii

Conditions: Mucopolysaccharidosis Type IIIA; Mucopolysaccharidosis Type IIIB

Summary: the purpose of this study is to assess rates of decline in motor and cognitive functional measures, and to assess potential biomarkers, in order to identify potential outcome measure appropriate for use in therapeutic clinical trials.

mucopolysaccharidosis (mps) type iii (sanfilippo syndrome) is a group of four devastating genetic diseases that result in the abnormal accumulation of glycosaminoglycans in body tissues. in mpsiii the predominant symptoms occur due to accumulation within the central nervous system (cns), including the brain and spinal cord, resulting in cognitive decline, motor dysfunction, and eventual death. in anticipation for future therapeutic studies for mpsiiia and mpsiiib, we are performing a natural history study to identify the following: 1. individual rates of decline in motor and cognitive function in a cohort of potential clinical trial patients 2. the natural history of outcome measures in order to assess their appropriateness as outcomes in an eventual trial 3. baseline functional data in patients who will be potential candidates for an eventual trial 4. biomarkers of disease progression over a 12-month interval, including changes in brain mri and in cerebrospinal fluid patients in this study will need to come to nationwide children's hospital in columbus, ohio, three times. at each of these three time points, cognitive outcome measures will be assessed: at baseline (visit 1), 6 months (visit 2), and at 12 months (visit 3). at baseline (visit 1) and 12 months (visit 3), an mri and a lumbar puncture will be performed.

Eligibility criteria:
inclusion criteria: 1. age 2 years old or greater 2. confirmed diagnosis of mpsiiia or mpsiiib by either of two methods: 1. no detectable or significantly reduced naglu (mpsiiib) or sgsh (mpsiiia) activity in serum or leukocyte assay 2. genomic dna mutation analysis demonstrating a homozygous or compound heterozygous mutations in the naglu (mpsiiib) or sgsh (mpsiiia) genes 3. clinical history of or examination features of neurologic dysfunction. exclusion criteria: 1. inability to participate in the clinical evaluations 2. presence of a concomitant medical condition that precludes lumbar puncture or use of anesthetics 3. inability to be safely sedated in the opinion of the clinical anesthesiologist

Keywords: mucopolysaccharidosis mps sanfilippo
evaluation of immune function in post-surgical and autoimmune hypoparathyroidism (empathy)

Conditions: Hypoparathyroidism; Hypoparathyroidism Postprocedural; Hypoparathyroidism Due to Impaired Parathormone Secretion

Summary: this is an observational pilot study for the evaluation of immune function, infectious diseases, psychometric status and quality of life in patients with hypoparathyroidism compared to healthy controls.

this is an observational pilot study for the evaluation of immune function, infectious diseases, psychometric status and quality of life in patients with hypoparathyroidism compared to healthy controls. all patients with hypoparathyroidism will be on established conventional therapy with calcium supplements and calcitriol. according to guidelines, possible confounding factors (i.e. vitamin d, serum magnesium levels) will be evaluated at screening visit. age-, sex- and bmi- matched healthy controls will be enrolled. patients and controls will undergo a screening visit (v0) and a baseline visit (v1) in the following month. the primary outcome will be the immune profiling of patients with hypoparathyroidism compared to healthy controls by the quantification of peripheral blood mononuclear cells (pbmc) subpopulations assessed by flow cytometry. secondary outcome measures will be: functional evaluation of pbmc cytokine secretion assessed by flow cytometry evaluation of calcium signaling components expression compared to healthy controls evaluation of pthr1 expression in immune cells compared to healthy controls evaluation of inflammatory cytokines production compared to healthy controls. evaluation of quality of life compared to healthy controls. quality of life will be measured by short form (sf)-36-item health survey total score, sf-36-item health survey physical component summary score and sf-36-item health survey mental component summary score. evaluation of infectious diseases frequencies and severity compared to healthy controls. infectious diseases will be evaluated by an adaptation of infectious diseases questionnaire (gnc). psychometric evaluation by self-administered questionnaires: beck depression index, middlesex hospital questionnaire. sleep disturbances evaluation by the pittsburgh sleep quality index (psqi) self reported questionnaire.

Eligibility criteria:
inclusion criteria: * previously diagnosed (at least 6 months before enrolment) hypoparathyroidism which required daily calcium (≥1000mg/die) and calcitriol therapy; * signed informed consent to participate in the study. exclusion criteria: * transient hypoparathyroidism; * history of neoplasms, radiotherapy or chemotherapy in the last 5 years; * clinical or laboratory signs of significant respiratory, hepatobiliary, or pancreatic disease; * severe infections, surgery, trauma requiring hospitalization within 3 months before enrolment; * severe chronic kidney disease (stage 4-5); * any active blood or rheumatic disorders in the last 5 years

Keywords: parathormone hypoparathyroidism parathyroid hypocalcemia immunity immune function quality of life sleep disturbances parathyroid hormone
dexmedetomidine on brain injury patients

Conditions: Brain Injuries

Summary: the aim of the study is to check whether dexmedetomidine has neuroprotective properties in brain injury patients. the enrolled 60 patients will be divided into two groups; group 1(n=30): are the patients who will receive dexmedetomidine. group 2 (n=30): are the patients who represent the control group.

1. approval will be obtained from the research ethics committee of faculty of pharmacy, damanhour university. 2. all participants must agree to take part in this clinical study and provide informed consent. 3. the required sample size will be calculated. 4. 60 patients with brain injury will be enrolled from the intensive care department, damanhour medical national institute. 5. serum samples will be collected for measuring the biomarkers. 6. all enrolled 60 patients will be mentioned as two groups; group 1(n=30): are the patients who will receive dexmedetomidine. group 2 (n=30): are the patients who represent the control group. 7. all patients will be followed up during their stay in the intensive care department. 8. during their stay in the intensive care department, step 5 will be repeated. 9. statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. 10. measuring outcomes: the primary outcome is measuring the neuroprotection provided by dexmedetomidine reflected by change in patients' symptoms, while secondary outcome is the change in the level of biomarkers from baseline to post-treatment. 11. results, discussion, conclusion, and recommendations will be given.

Eligibility criteria:
inclusion criteria: * 60 patients with brain injury with age ranging from 18 to 70 years, there are no limits to gender. exclusion criteria: * patients with significant liver impairment * patients with known heart failure * patients with hypotension * patients with bradycardia
efficacy and safety in patients with type 2 diabetes mellitus, cardiovascular disease and hypertension

Conditions: Type 2 Diabetes Mellitus; Cardiovascular Disease; Hypertension; Inadequate Glycaemic Control

Summary: this study is carried out to assess whether dapagliflozin lowers blood glucose, body weight and blood pressure, when added to patients existing medications and how it compares with their usual treatment without added dapagliflozin. safety data will be collected and analysed to confirm that treatment with dapagliflozin is safe and well tolerated in patients who have diabetes, cardiovascular disease and hypertension.


Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus. * cardiovascular disease * hypertension exclusion criteria: * patients with type 1 diabetes or diabetes insipidus * patients with 3 or more oral anti-hyperglycaemic drugs with or without insulin and/or poorly controlled diabetes * any clinically significant illness, which would compromise the patient's safety and their participation in the study

Keywords: dapagliflozin diabetes cardiovascular disease hypertension
dose-dependent effect of rosuvastatin on long-term clinical outcomes after pci

Conditions: Coronary Artery Disease; Coronary Disease; Cardiovascular Diseases

Summary: this study is a prospective, randomized, open-label, single-center trial designed to compare the 30 month-safety and efficacy between low-dose (5mg/dl) and high-dose (20mg/dl) rosuvastatin treatment for patients with coronary artery disease after percutaneous coronary intervention with the newer drug-eluting stent.

with the development of the newer generation drug-eluting stents, percutaneous coronary intervention (pci) has been a feasible treatment for patient with coronary artery disease. however, stent failures including in-stent restenosis and stent thrombosis have been still problematic. moreover, neoatherosclerosis, which is the atherosclerotic process developed in the neointima within the implanted stent, has been reported to be associated with neoatherosclerotic plaque rupture and contribute to the development of acute coronary syndrome in patients after drug-eluting stent (des) implantation. in this perspective, recent aha/acc and esc guidelines recommend the high-dose(intensity) statin therapy for patients performed pci. however, the efficacy of the high-dose(intensity) statin therapy on cardiovascular outcomes is still controversial. several meta-analysis failed to show the benefit of the high-dose(intensity) statin therapy to reduce the mortality. moreover, clear evidence for the benefits of such high-dose(intensity) statin therapy has no yet been demonstrated in east asian patients. this trial was designed to compare the 30 month-safety and efficacy between low-dose (5mg/dl) and high-dose (20mg/dl) rosuvastatin treatment for patients with coronary artery disease after pci in the era of the newer generation des era.

Eligibility criteria:
inclusion criteria: * patients underwent percutaneous coronary intervention with drug-eluting stent; exclusion criteria: * taking other drugs which can influence the lipid profile (eg. niacin, fibrates; * serum creatinine level \> 2.0 mg/dl * serum aspartate transaminase \> 3 times upper limit of normal * serum alanine transaminase \> 3 times upper limit of normal * having anaphylactic reaction for rosuvastatin; * having the other contraindications for rosuvastatin; * having plan to be pregnant; * having life expectancy less than 1 year

Keywords: rosuvastatin calcium percutaneous coronary intervention drug-eluting stents patient outcome assessment biomarkers hyperlipidemias dyslipidemias atherosclerosis hydroxymethylglutaryl-coa reductase inhibitors anticholesteremic agents hypolipidemic agents lipid regulating agents
temperature and analgesia monitoring during cardial parmonary bypass

Conditions: Coronary Artery Disease

Summary: 1. investigator will apply ioc2 to reflect the depth of analgesic during hypothermia in cpb period. 2. effectiveness of ioc2 monitoring for anesthetic depth versus commonly used vital sign monitoring based on factors such as blood pressure and heart rate. 3. evaluate the other sedation co-relation measurement, include bis , ioc2 to reflected the consciousness during the operation. 4. evaluate the other hemodynamic index, include co, svv, cvp, ppv to reflect the circulation function , and the effect to the ioc2 and ioc1. 5. describe the trend of all the measurement. detect the variation of the index during the temperature change during the cpb.

in this study, 1. investigator will apply ioc2 to reflect the depth of analgesic during hypothermia in cpb period. 2. furthermore, investigator evaluated the effectiveness of ioc2 monitoring for anesthetic depth versus commonly used vital sign monitoring based on factors such as blood pressure and heart rate. 3. evaluate the other sedation co-relation measurement, include bis , ioc2 to reflected the consciousness during the operation. 4. evaluate the other hemodynamic index, include co, svv, cvp, ppv to reflect the circulation function , and the effect to the ioc2 and ioc1. 5. describe the trend of all the measurement. detect the variation of the index during the temperature change during the cpb.

Eligibility criteria:
inclusion criteria: * undergoing coronary artery bypass surgery exclusion criteria: * change the surgery planning during the operation
effects of high intensity laser therapy (hilt) in patients with subacromial impingement syndrome

Conditions: Subacromial Impingement Syndrome

Summary: the aim of this study is to determine the effects of high intensity laser therapy (hilt) in patients with subacromial impingement syndrome (sis). this study aims to compare the effects of hilt alone and hilt and therapeutic exercise combination on shoulder pain, rom, joint position sense (jps), muscle strength and function.the investigators hypothesized that shoulder pain, rom, jps, muscle strength and functionality would improve with both treatments but that hilt combined with exercise would result in better outcomes than hilt alone.

30 patients with sis will be randomized into two groups. pain intensity will be assessed with visual analogue scale (vas), pain-free and normal range of motion (rom) with goniometer, joint position sense (jps) with inclinometer, muscle strenght with hand-held dynamometer, and shoulder functionality with constant murley score (cms) and shoulder pain and disability index (spadi) in a pretest-posttest design. hilt group (n=15) will receive only hilt for 10 sessions, 3 days a week on alternate days. hilt\& exercise group (n=15) will receive exercise treatment in addition to hilt for the same duration of time.

Eligibility criteria:
inclusion criteria: * diagnosed as sis (≥3 positive of 5 impingement tests: neer's sign, hawkins and kennedy, empty can, painful arc of abduction and external rotation resistance tests) * no history of shoulder injury and/or shoulder symptoms requiring treatment other than sis for the last 1 year * shoulder pain less than 7/10 of visual analogue scale * being able to elevate the shoulder over 140 degrees exclusion criteria: * history of upper extremity fracture, shoulder surgery * frozen shoulder * full-thickness rotator cuff (rc) tear * shoulder instability, systemic musculoskeletal disease * shoulder pain with cervical spine motion, * having any of the contraindications of hilt.

Keywords: subacromial impingement syndrome high intensity laser therapy laser therapy shoulder pain